Buprenorphine and its formulations: a comprehensive review.

IF 3 Q3 PSYCHOLOGY, CLINICAL Health Psychology Research Pub Date : 2022-08-20 eCollection Date: 2022-01-01 DOI:10.52965/001c.37517

Salomon Poliwoda, Nazir Noor, Jack S Jenkins, Cain W Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M Kaye, Alan D Kaye

{"title":"Buprenorphine and its formulations: a comprehensive review.","authors":"Salomon Poliwoda, Nazir Noor, Jack S Jenkins, Cain W Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M Kaye, Alan D Kaye","doi":"10.52965/001c.37517","DOIUrl":null,"url":null,"abstract":"<p><p>Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.</p>","PeriodicalId":51865,"journal":{"name":"Health Psychology Research","volume":" ","pages":"37517"},"PeriodicalIF":3.0000,"publicationDate":"2022-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392838/pdf/healthpsychologyresearch_2022_10_3_37517.pdf","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Psychology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52965/001c.37517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}

引用次数: 10

Abstract

Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

丁丙诺啡及其制剂综述。

丁丙诺啡是一种新型长效镇痛药，主要用于镇痛和阿片类药物使用障碍。就其药效学而言，它是mu受体的部分激动剂，kappa受体的逆激动剂和delta受体的拮抗剂。为了达到镇痛的目的，我们开发了三种丁丙诺啡制剂:静脉注射制剂(Buprenex®)、透皮贴剂制剂(Butrans®)和口腔膜制剂(Belbuca®)。与阿片类药物依赖相关的制剂有皮下缓释片(Sublocade®)、皮下植入片(Probuphine®)和舌下片剂(Subutex®)。最后，为了避免丁丙诺啡对阿片类药物依赖的滥用，研究人员开发了两种与纳洛酮配对的联合制剂:薄膜制剂(Suboxone®)和片剂制剂(Zubsolv®)。在这篇综述中，我们介绍了每种配方的细节，以及它们之间的异同和临床考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊